close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

42.98 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
News headline image
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private ↗
This week's Deal Dispatch has updates on Raizen, Walgreens, TikTok and Canoo. Plus: the FTC is blocking mergers like it's 2017 again. 
Via Benzinga
News headline image
Why Surmodics Stock Is Falling On Friday ↗
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR. 
Via Benzinga
News headline image
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
From Surmodics, Inc.
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing This Month ↗
 
Via Benzinga
News headline image
Surmodics Earnings Analysis: Q1 Recap ↗
 
Via Benzinga
News headline image
Assessing Surmodics: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
From Surmodics, Inc.
Via Business Wire
News headline image
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024 ↗
SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
News headline image
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
News headline image
SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
From Surmodics, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals ↗
Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal. 
Via Investor's Business Daily
News headline image
Why Is Medical Coating Specialist Surmodics Trading Higher On Wednesday? ↗
Surmodics will be acquired by GTCR for $43.00 per share, totaling $627 million. This 41.1% premium reflects Surmodics' advancements in surface modification for medical devices and IVD technologies. 
Via Benzinga
News headline image
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
From Surmodics, Inc.
Via Business Wire
News headline image
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024 ↗
SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today